Previous 10 | Next 10 |
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand’s board. “We are very ...
2023-09-25 17:28:21 ET More on Ligand Pharmaceuticals Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Historical earnings data for Ligand Pharmaceuticals Financial information for Ligand Pharmaceuticals Novan craters as company files for bankrup...
2023-09-22 09:29:56 ET More on Jazz Pharma Seeking Alpha’s Quant Rating on Jazz Pharmaceuticals Historical earnings data for Jazz Pharmaceuticals Financial information for Jazz Pharmaceuticals Jazz Pharmaceuticals: Depressed Valuation Opens Up Potentia...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ), (“Jazz”) has been granted marketing authorization by the European Commission (EC) for Enrylaze ® (JZP458; a recombinant Erwinia asparaginase or crisantas...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) (“Travere”) today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head Phase 3 PROTECT Study of FILSPARI ® ...
2023-09-18 18:46:31 ET More on Ligand Pharmaceuticals Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Historical earnings data for Ligand Pharmaceuticals Financial information for Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out ...
Ligand retains all Pelican commercial royalties and will own 49.9% of Primrose Bio, Inc. as a stand-alone private company with leading technologies in synthetic biology Ligand contributes $15 million in exchange for economic interest in select Primrose programs Ligand improves cash expens...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on September 1, 2023, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 50,000 shares of its common sto...
2023-09-01 11:37:32 ET Summary Ligand Pharmaceuticals Incorporated generates revenue through licensing technologies, contractual fees, and the sale of Captisol, a modified cyclodextrin used in drug development. Captisol has been a major source of revenue for Ligand, particularly t...
2023-08-10 08:06:33 ET More on Johnson & Johnson Future Prospects For Johnson & Johnson Following Strong Q2 Performance Johnson & Johnson: Resilient, But Clarification On Liability Issue Is Needed Johnson & Johnson ( JNJ ) Q2 2023 Earnings Call ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc...
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...